<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00705900</url>
  </required_header>
  <id_info>
    <org_study_id>06-LCDPOP</org_study_id>
    <nct_id>NCT00705900</nct_id>
  </id_info>
  <brief_title>LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis</brief_title>
  <official_title>A Randomized, Single-Blind, Active Control, 18-Week Study to Evaluate the Safety and Efficacy of A New Twice-Daily, Topically Applied LCD Solution vs. Calcipotriol Cream for the Treatment of Adult Subjects With Moderate Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeoStrata Company, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeoStrata Company, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and effectiveness of a new topical LCD
      solution and a commercially available calcipotriol (Vitamin D) cream in reducing the symptoms
      of plaque psoriasis and improving the quality of life in adults.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">November 2008</completion_date>
  <primary_completion_date type="Actual">November 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference in percent reduction in Psoriasis Area and Severity Index (PASI) Scores between treatment arms</measure>
    <time_frame>12 weeks of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in PLASI, PEASI, Physician Global Assessment (PGA), Pruritus, and Dermatology Life Quality Index (DLQI) Scores between treatment arms</measure>
    <time_frame>Week 12 and Week 18</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Chronic Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LCD Solution: 2 applications / day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Calcipotriol cream: 2 applications / day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LCD</intervention_name>
    <description>2 applications / day for 12 weeks</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>calcipotriol</intervention_name>
    <description>2 applications / day for 12 weeks</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Dovonex Cream (50 mcg/g 0.005%)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18 years of age or older

          -  able and willing to provide written informed consent

          -  diagnosed with chronic plaque psoriasis

          -  3% to 15% body surface area involved

          -  in good general health

        Exclusion Criteria:

          -  other current treatments for psoriasis

          -  renal or liver dysfunction

          -  pregnant or nursing
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra B Kimball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusettes General Hospital / Brigham Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mass General Hospital: Clinical Unit for Research Trials in Skin</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 25, 2008</study_first_submitted>
  <study_first_submitted_qc>June 26, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2008</study_first_posted>
  <last_update_submitted>November 17, 2008</last_update_submitted>
  <last_update_submitted_qc>November 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Alexandra B. Kimball, MD</name_title>
    <organization>Massachusettes General Hospital / Brigham Women's Hospital</organization>
  </responsible_party>
  <keyword>psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcipotriene</mesh_term>
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>November 17, 2014</submitted>
    <returned>November 21, 2014</returned>
    <submitted>April 1, 2015</submitted>
    <returned>April 2, 2015</returned>
    <submitted>April 17, 2015</submitted>
    <returned>April 21, 2015</returned>
    <submitted>July 22, 2015</submitted>
    <returned>July 24, 2015</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

